| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 207,834 | - | - | - |
| Research and development | 82,993 | 74,226 | 70,886 | 57,152 |
| General and administrative | 16,389 | 14,580 | 13,503 | 9,741 |
| Total operating expenses | 99,382 | 88,806 | 84,389 | 66,893 |
| Income (loss) from operations | 108,452 | -88,806 | -84,389 | -66,893 |
| Interest income and other income, net | 10,792 | 11,315 | 12,211 | 15,072 |
| Net income (loss) | 119,244 | -77,491 | -72,178 | -51,821 |
| Unrealized gains on marketable securities | 531 | -64 | 773 | 5,252 |
| Comprehensive income (loss) | 119,775 | -77,555 | -71,405 | -46,569 |
| Earnings per share, basic | 1.35 | -0.88 | -0.82 | -0.6 |
| Earnings per share, diluted | 1.33 | -0.88 | -0.82 | -0.6 |
| Weighted average number of shares outstanding, basic | 88,526,781 | 88,472,197 | 88,356,335 | 86,188,510 |
| Weighted average number of shares outstanding, diluted | 89,690,878 | 88,472,197 | 88,356,335 | 86,188,510 |
IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences, Inc. (IDYA)